BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
Author: Business Wire
Visus Therapeutics to Host First Capital Markets Day in New York City on August 31, 2021
SEATTLE–(BUSINESS WIRE)–Visus Therapeutics to host its First Capital Markets Day in New York City on August 31, 2021 from 10am to 2pm ET at Convene, 530 Fifth Avenue.
Heru, the Wearable Diagnostic and Vision Augmentation Leader, Launches Commercial Availability of re:Vive in Partnership with Vision Source
HOUSTON–(BUSINESS WIRE)–Heru launches commercial availability of re:Vive, its wearable diagnostics and visual field application, with launch partner, Vision Source.
Eyevensys lève 12 millions de dollars dans un tour de table série B Plus
PARIS et CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Eyevensys, une société privée de biotechnologie au stade clinique qui développe des thérapies géniques non virales pour les maladies oculaires, annonce aujourd’hui qu’elle a levé 12 millions de dollar…
Encellin Closes $5.9M Seed Financing Co-Led by Khosla Ventures and SV Latam Capital
SAN FRANCISCO–(BUSINESS WIRE)– #biotech–Encellin Closes $5.9M Seed Financing co-led by Khosla Ventures and SV Latam Capital
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended J…
LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for …
NovaBay Pharmaceuticals to Hold Second Quarter 2021 Conference Call on August 12
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and six months ended June 30, 2021 after market close on Thursday, August 12, 2021 and will hold an invest…
Global Dry Eye Disease Drug Pipeline Research Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Disease – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Dry Eye Disease – Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipel…
Iveric Bio to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced that Pravin U. Dugel, M.D., President, will participate in a panel at the Wedbush Conference on Wed., Aug. 11 at 8:00 a.m. ET.
STAAR Surgical Reports Record Second Quarter Net Sales of $62.4 Million Up 77% Y/Y and Increases Outlook for 2021
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended …
Eyevensys Raises $12M in a Series B Plus Funding Round
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)– #Eyevensys–Eyevensys, a private biotech developing gene therapies for ophthalmic diseases, today announces it has raised $12M in a Series B Plus funding round.
RightEye Launches Eye Care’s First Automated Sensorimotor Exam for Binocular Vision Testing
BETHESDA, Md.–(BUSINESS WIRE)–RightEye LLC, an advanced eye-tracking technology company, has launched the world’s first automated, quantitative sensorimotor exam system. RightEye Sensorimotor is an easy-to-use, all-in-one examination system that opto…
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the t…
Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced financial and operating results for the quarter ended June 30, 2021 and provided a general business update.
Topcon Healthcare to Partner with RetInSight
OAKLAND, N.J.–(BUSINESS WIRE)– #TopconHealthcare–Topcon Healthcare of Oakland, NJ, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will partner with RetInSight GmbH, a developer…
Worldwide Corneal Implants Industry to 2026 – North America Accounted for the Largest Share in the Global Market – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Corneal Implants Market- Growth, Trends, COVID-19 Impact and Forecasts (2021 – 2026)” report has been added to ResearchAndMarkets.com’s offering. The corneal implants market is projected to register a CAGR of more than 6% …
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the BTIG Virtual Biot…
Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK–(BUSINESS WIRE)–Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to five newly hired employees.
Retinal Detachment Market Insights, Competitive Landscape and Market Forecast Report 2021-2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinal Detachment – Market Insights, Competitive Landscape and Market Forecast – 2026” drug pipelines has been added to ResearchAndMarkets.com’s offering. This ‘Retinal Detachment – Market Insights, Competitive Landscape …